Currently under FDA review, CS-8635 combines three powerful blood pressure treatments with different mechanisms of action, Benicar (olmesartan medoxomil), amlodipine and hydrochlorothiazide.
Cempra Pharmaceuticals announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA, the company’s oral, anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic.
The Food and Drug Administration is looking into data suggesting a group of prostate cancer drugs increase the risk of diabetes and heart disease.
An Albuquerque woman has filed a lawsuit over a vaccine intended to protect women from cervical cancer, alleging it caused physical and behavioral problems in her teenage daughter.
Gilead Sciences, Inc. has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278.
Thermo Fisher Scientific Inc. announced the latest release in its GRAMS Suite of spectroscopy software, an industry standard solution for visualizing, processing, reporting and managing spectroscopy data.
Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.
Researchers at Indiana University School of Medicine have identified a mechanism that causes inflammation in asthma and other allergic diseases, a discovery that could lead to new targets to control such allergic reactions.
ProImmune Ltd offers the CFSE T cell proliferation assays for immunogenicity risk assessment used in the design and selection of biological drug leads at the preclinical stage.
BrainCells Inc. announced that the United States Patent and Trademark Office issued the company Patent Number 7,678,808 entitled, “5 HT Receptor Mediated Neurogenesis.”
The Global Alliance for TB Drug Development (TB Alliance) and AstraZeneca announced at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB), including drug-resistant strains of the disease.
A new white paper, “Advanced Detection of Mycoplasmas: How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers,” explores relevant mycoplasma characteristics, established testing solutions, and the use of real-time PCR analysis as an alternative testing method for fast, preliminary mycoplasma detection.
BacTrace antibodies to infectious disease agents include Borrelia burgdorferi, Borrelia species, Legionella species and Helicobacter pylori.
Radix BioSolutions will integrate a Gyrolab xP workstation into its immunoassay development programs.